Medical Condition News

RSS

FDA issues letter directing GSK to revise product labeling for Serevent and Advair

GlaxoSmithKline today announced that it has received a letter from the U.S. Food and Drug Administration directing revisions to product labeling for its respiratory products Serevent and Advair. The letter concludes discussions between GSK and the agency following FDA advisory committee meetings regarding the safety profile of long-acting beta2-agonists in the treatment of asthma, including salmeterol, the active ingredient in Serevent and one of the active ingredients in Advair.

3 Jun 2010

Phase II trial of NUVIGIL Tablets for treatment of schizophrenia fails to meet primary endpoint: Cephalon

Cephalon, Inc. today announced that the primary endpoint was not met in a Phase II clinical trial that examined NUVIGIL (armodafinil) Tablets [C-IV] as an adjunctive therapy for the treatment of the negative symptoms of schizophrenia, which include problems with motivation and emotional withdrawal.

3 Jun 2010

ACT Biotech's Telatinib receives orphan drug designation from FDA for treatment of gastric cancer

ACT Biotech Inc., a privately held biotechnology company developing a portfolio of oral kinase inhibitors as anti-cancer drugs, announced today that the company's highly selective oral kinase inhibitor, Telatinib, has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of gastric cancer.

3 Jun 2010

NICE updates recommendations on diagnosis, treatment of low risk BCCs

The National Institute for Health and Clinical Excellence has updated its recommendations on the diagnosis and treatment of 'low risk' basal cell carcinomas.

3 Jun 2010

Phase III study of Afinitor tablets in patients with advanced pancreatic NET meets primary endpoint

Novartis Pharmaceuticals Corporation announced today that a Phase III study of Afinitor (everolimus) tablets plus best supportive care met its primary endpoint, showing the drug significantly extended progression-free survival, or time without tumor growth, in patients with advanced pancreatic neuroendocrine tumors.

3 Jun 2010

NCCTG study testing methylphenidate in treatment of cancer-related fatigue completed

Cancer-related fatigue is often a major problem for cancer patients, beginning at diagnosis, during treatment and after completing therapy. Researchers at Mayo Clinic and the North Central Cancer Treatment Group recently completed a study testing methylphenidate in the treatment of cancer-related fatigue and found that, while it did not improve fatigue for a broad group of patients, the data did not rule out a benefit for those with stage III/IV cancer.

3 Jun 2010

Chili peppers may cause weight loss and fight fat buildup, says study

Scientists are reporting new evidence that capsaicin, the stuff that gives chili peppers their kick, may cause weight loss and fight fat buildup by triggering certain beneficial protein changes in the body. Their study, which could lead to new treatments for obesity, appears in ACS' monthly Journal of Proteome Research.

3 Jun 2010

UTHealth, UH awarded $150,000 grant to find cure and better treatments for Alzheimer's disease

Cure Alzheimer's Fund recently awarded the University of Texas Health Science Center at Houston and the University of Houston a $150,000 grant to fund innovative research on Alzheimer's disease, which currently affects 5.3 million Americans and their families and is the most common cause of dementia in the elderly.

3 Jun 2010

Research explains brain's susceptibility to dystonia

Why do some diseases affect only specific organs, leaving others invulnerable? Researchers from the University of Michigan have found neural tissue contains imbalanced levels of proteins, which may explain the brain's susceptibility to a debilitating childhood movement disorder.

3 Jun 2010

Researchers describe chain of molecular events that increase one's risk of skin cancer

As people head to the beach this summer, very few if any, really know how likely they are to develop skin cancer from their outdoor fun. That's about to change, thanks to a new discovery by an international team of scientists that makes it possible for doctors to access people's personal risk for skin cancer.

3 Jun 2010

Tips to prevent back injuries

Whether moving to a new home or packing up for the semester, the physical intensity of moving can be extreme. Packing boxes, moving heavy furniture, emptying overhead cabinets -- all come with some risk for injury, especially to your back. Back pain is one of the most common reasons for Americans visit their doctors.

3 Jun 2010

Ablation technique as affective as conventional surgery for treating kidney cancer

A minimally invasive technique used to destroy kidney tumors with an electrically controlled heating probe showed similar effectiveness as surgical removal of tumors in curbing cancer recurrence rates for up to five years after treatment.

3 Jun 2010

Canadian researchers: Probiotic found in breast milk reduces painful cramping in gut

Here's another reason to breast feed your baby: Canadian researchers have discovered how a probiotic found in breast milk reduces or eliminates painful cramping in the gut. In a new research report published online in the FASEB Journal, these scientists use mice to show that a specific strain of Lactobacillus reuteri decreases the force of muscle contractions in the gut within minutes of exposure.

3 Jun 2010

New breakthrough may help understand human obesity and eating disorders

A nutrient that's common to all living things can make hibernating marmots hungry - a breakthrough that could help scientists understand human obesity and eating disorders, according to a new study by a Colorado State University biologist.

3 Jun 2010

Insulin pills to manage diabetes are finally moving ahead in clinical trials

After years of research and anticipation, insulin pills that could make it easier for millions of patients worldwide to manage diabetes are finally moving ahead in clinical trials and a step-closer to the medicine cabinet. That's among the topics highlighted in a two-part cover story on drug manufacturing in the current issue of Chemical & Engineering News, ACS' weekly newsmagazine.

3 Jun 2010

Discovery provides new therapeutic target to prevent brain function loss

Researchers at Mount Sinai School of Medicine have found that certain types of specializations on nerve cells called "spines" are depleted as a person ages, causing cognitive decline in the part of the brain that mediates the highest levels of learning. These spines receive an important class of synapses that are involved with the process of learning.

3 Jun 2010

Three in five Americans may develop noise-induced hearing loss

Use of ear bud headphones by youngsters may save your ears from being assaulted by the noise of your teenagers' music or electronic game but are they damaging your child's hearing?

3 Jun 2010

Light therapy may be alternative treatment for prostate cancer

Cliff Berkman is working on a better way—one that specifically targets prostate cancer cells and causes a type of natural death that spares surrounding tissues from damage.

3 Jun 2010

FDA accepts Eisai's NDA for rabeprazole sodium extended-release 50 mg

Eisai Inc. (Headquarters: Woodcliff Lake, NJ; Chairman and CEO: Hajime Shimizu), a U.S. subsidiary of Eisai Co., Ltd. (Headquarters: Tokyo; President and CEO: Haruo Naito) today announced that the U.S. Food and Drug Administration has accepted Eisai's New Drug Application for rabeprazole sodium extended-release 50 mg for the healing and maintenance of healing of erosive gastroesophageal reflux disease, and for the treatment of symptomatic GERD.

3 Jun 2010

In 2008, 63% of cancer deaths were in developing countries

By 2030, cancer could claim the lives of 13.3 million annually, almost double the number of patients who died from the illness in 2008, the U.N.'s International Agency for Research on Cancer (IARC) said Tuesday, Agence France-Presse reports.

3 Jun 2010

Medical Condition News

FDA issues letter directing GSK to revise product labeling for Serevent and Advair

Phase II trial of NUVIGIL Tablets for treatment of schizophrenia fails to meet primary endpoint: Cephalon

ACT Biotech's Telatinib receives orphan drug designation from FDA for treatment of gastric cancer

NICE updates recommendations on diagnosis, treatment of low risk BCCs

Phase III study of Afinitor tablets in patients with advanced pancreatic NET meets primary endpoint

NCCTG study testing methylphenidate in treatment of cancer-related fatigue completed

Chili peppers may cause weight loss and fight fat buildup, says study

UTHealth, UH awarded $150,000 grant to find cure and better treatments for Alzheimer's disease

Research explains brain's susceptibility to dystonia

Researchers describe chain of molecular events that increase one's risk of skin cancer

Tips to prevent back injuries

Ablation technique as affective as conventional surgery for treating kidney cancer

Canadian researchers: Probiotic found in breast milk reduces painful cramping in gut

New breakthrough may help understand human obesity and eating disorders

Insulin pills to manage diabetes are finally moving ahead in clinical trials

Discovery provides new therapeutic target to prevent brain function loss

Three in five Americans may develop noise-induced hearing loss

Light therapy may be alternative treatment for prostate cancer

FDA accepts Eisai's NDA for rabeprazole sodium extended-release 50 mg

In 2008, 63% of cancer deaths were in developing countries

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News